Growth Metrics

Insulet (PODD) Acquisitions (2022 - 2023)

Insulet posted quarterly Acquisitions of $3.0 million for Q1 2023, down 88.46% year-on-year from $26.0 million in Q1 2022, and down 88.46% on a QoQ basis from $26.0 million in Q1 2022.

Insulet (PODD) has 2 years of Acquisitions data on file, last reported at $3.0 million in Q1 2023.

  • For the quarter ending Q1 2023, Acquisitions fell 88.46% year-over-year to $3.0 million; the trailing twelve-month figure through Dec 2023 stood at $3.0 million (down 88.46% YoY), and the FY2023 full-year result was $3.0 million, down 88.46% from the prior year.
  • Acquisitions for Q1 2023 stood at $3.0 million, down from $26.0 million in the prior quarter.
  • Across five years, Acquisitions topped out at $26.0 million in Q1 2022 and bottomed at $3.0 million in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 22.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 523.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -268.10 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 2.30 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Insulet 10.37 Bn 9.89 Bn 529.10 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 3.00 Mn
Mar 31, 2022 26.00 Mn